Navigation Links
AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
Date:6/3/2008

WOBURN, Mass., June 3 /PRNewswire/ -- AdvanDx today announced the FDA 510(k) submission of Yeast Traffic Light PNA FISH(TM) for detection of Candida yeast species from positive blood cultures. Yeast Traffic Light(TM) is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days. Candidemia, a bloodstream infection caused by Candida species is one of the most serious hospital acquired infections, afflicting over 24,000 patients in the U.S. every year. Immunocompromised transplantation, oncology and AIDS patients are especially at risk for contracting the infection with mortality rates as high as 50%.(1) While identification of the infecting Candida species is used to guide effective antifungal therapy, conventional laboratory methods can take up to 5 days or longer. Yeast Traffic Light(TM) will for the first time enable laboratories to rapidly detect, in a single test, up to five Candida species directly from positive blood cultures including C. albicans and C. parapsilosis, C. tropialis, and C. glabrata and C. krusei in hours instead of days. The rapid results should enable clinicians to provide early, effective and appropriate antifungal therapy for patients with candidemia.

A recent study by Della-Latta et al. presented at the 2008 ECCMID meeting in Barcelona, Spain demonstrated that rapid identification of Candida species using PNA FISH can significantly impact antifungal selection and care for patients with Candidemia. In the study, rapid identification of C. albicans led to a switch to the antifungal drug fluconazole for 70% of the patients that had been on caspofungin, a newer, more broad-spectrum but more expensive antifungal drug. At the same time, rapid identification of C. glabrata, a Candida species with high levels of resistance to fluconazole, led to an 81% switch to caspofungin for those patients that had otherwise been given fluconazole. Based on the study results, the authors concluded that the PNA FISH test "can impact the appropriate selection of the most effective antifungal therapy, thereby making it a clinically relevant diagnostic assay." (2)

"The Yeast Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections," said Thais T. Johansen, President and CEO of AdvanDx. "The test will ultimately enable clinicians to provide more appropriate care, improve antifungal selection and hopefully improve outcomes for their patients," Johansen concluded.

About Bloodstream Infections

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The infection is detected when a culture of the patient's blood, i.e. a blood culture, turns positive with bacteria and yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.

About PNA FISH(TM)

PNA FISH is an easy-to-use and highly sensitive and specific fluorescence in situ hybridization (FISH) assay that uses PNA (peptide nucleic acid) probes to target species specific ribosomal RNA (rRNA) in bacteria and yeast. PNA FISH tests enable microbiology labs to provide rapid and accurate identification of bloodstream pathogens directly from positive blood cultures in hours instead of days. Clinical studies show that rapid identification of bloodstream pathogens using PNA FISH tests leads to more appropriate patient therapy that saves lives and reduces unnecessary antibiotic use, patient length of stay and hospital costs.

About AdvanDx

AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit http://www.AdvanDx.com

CONTACTS:

Company Contact: Media Inquiries:

Joen T. Johansen Joe Romano

Director of Marketing Partner

AdvanDx HighGround, Inc.

+1-339-227-4052 +1-781-939-5800 Ext 208

jtj@advandx.com jromano@highgroundinc.com

References:

1. Spellberg et al. Current Treatment Strategies for Disseminated

Candidiasis. Clin. Infec. Dis. 42: 244-251. 2005

2. Della-Latta et al. Impact of Rapid Identification of C. albicans and

C. glabrata Directly from Blood Cultures using PNA FISH Technology on

Selection of Antifungal Therapy. Poster 1382. ECCMID 2008.

Barcelona, Spain.


'/>"/>
SOURCE AdvanDx
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis ... type of groin injury, it occurs when the muscles around the pelvis become ... and around the lower torso, as well as accompanying tenderness and weakness. Without ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... time,” she said. , She thinks the coming week is going to be a very ... have to help my students.” , The award will allow the 4th grade teacher at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently ... and require expert user knowledge. In a live webinar on April 11th and ... yet highly accurate, determination of sodium. , It has long been known that ...
Breaking Medicine News(10 mins):